NCT05201066

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

← Hub

Registry fields

Overall status: ACTIVE_NOT_RECRUITING
Conditions: Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Study type: INTERVENTIONAL
Phase: PHASE2
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: decitabine, spartalizumab, sabatolimab, azacitidine, venetoclax, INQOVI (oral decitabine)
Lead sponsor: Novartis Pharmaceuticals (INDUSTRY)

Cached at: 2026-07-25 04:09:40

View on ClinicalTrials.gov

Brief summary

This study is intended to collect safety data from participants who completed the parent protocols but are still benefiting from study treatment. The study population consists of participants who tolerate study treatment of the parent studies. Collecting safety information from long-term exposure might offer the unique opportunity to detect rare Adverse Events.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report